Introduction

▼
The elevation of blood glucose levels stimulates both insulin secretion from pancreatic β-cells and insulin gene transcription. Insulin is the only hormone in the body able to decrease blood glucose levels. This important metabolic function of insulin is initiated by its binding to insulin receptor (IR) on the plasma membrane of target organs including the liver, muscle, and adipose tissue [ 1 -3 ] . IR undergoes conformational change to activate intrinsic tyrosine kinase activity and phosphorylates several substrates including insulin receptor substrates (IRSs), which lead to the activation of downstream signaling pathways. Insulin-induced transcription factors control metabolism by modulating the transcription rate of key enzyme genes. As a result, insulin decreases blood glucose by promoting glucose uptake into peripheral tissues, mainly muscle and adipose tissue cells, as well as by preventing the liver from producing glucose by suppressing glycogenolysis and gluconeogenesis. Thus, tran- 
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▼
The rat enhancer of split-and hairy-related protein-1 (SHARP-1) is a basic helix-loop-helix transcription factor. An issue of whether SHARP-1 is an insulin-inducible transcription factor was examined. Insulin rapidly increased the level of SHARP-1 mRNA both in vivo and in vitro. Then, signaling pathways involved with the increase of SHARP-1 mRNA by insulin were determined in H4IIE rat hepatoma cells. Pretreatments with LY294002, wortmannin, and staurosporine completely blocked the induction eff ect, suggesting the involvement of both phosphoinositide 3-kinase (PI 3-K) and protein kinase C (PKC) pathways. In fact, overexpression of a dominant negative form of atypical protein kinase C lambda (aPKCλ) signifi cantly decreased the induction of the SHARP-1 mRNA. In addition, inhibitors for the small GTPase Rac or Jun N-terminal kinase (JNK) also blocked the induction of SHARP-1 mRNA by insulin. Overexpression of a dominant negative form of Rac1 prevented the activation by insulin. Furthermore, actinomycin D and cycloheximide completely blocked the induction of SHARP-1 mRNA by insulin. Finally, when a SHARP-1 expression plasmid was transiently transfected with various reporter plasmids into H4IIE cells, the promoter activity of PEPCK reporter plasmid was specifi cally decreased. Thus, we conclude that insulin induces the SHARP-1 gene expression at the transcription level via a both PI 3-K/ aPKCλ/JNK-and a PI 3-K/Rac/JNK-signaling pathway; protein synthesis is required for this induction; and that SHARP-1 is a potential repressor of the PEPCK gene expression. circadian rhythms, hypoxia, or cellular diff erentiation [ 10 -12 ] . Recently, it has been shown that overexpression of SHARP-1 inhibited skeletal muscle diff erentiation and adipocyte diff erentiation [ 9 , 13 ] . In addition, functions of SHARP-1 and SHARP-2 as transcriptional repressors were reported in sterol regulatory element-binding protein-1c (SREBP-1c)-induced transcription [ 14 ] . A point mutation of the human DEC2 gene has been reported to regulate sleep length [ 15 ] . However, the regulation of the SHARP-1 gene expression in other cell types and the molecular mechanisms underlying its regulation as a transcription repressor remains elusive. We have previously reported that the expression levels of hepatic SHARP-2 mRNA increased when a high-carbohydrate diet was fed to normal rats, or when insulin was administered to diabetic rats [ 16 ] . We also reported that transcription of the rat SHARP-2 gene was induced by insulin via a phosphoinositide 3-kinase (PI 3-K) pathway [ 16 ] . In addition, overexpression of SHARP-2 in the primary cultured rat hepatocytes and rat H4IIE highly diff erentiated hepatoma cells decreased the levels of phosphoenolpyruvate carboxykinase (PEPCK) mRNA, which is the rate-limiting enzyme in hepatic gluconeogenesis [ 17 ] . Moreover, the promoter activity of the PEPCK gene was impaired by the overexpression of SHARP-2 protein [ 17 ] . From these results, we hypothesize that SHARP-2 would be an important transcription factor involved in the regulation of blood glucose level. In this study, we investigated the eff ect of insulin on SHARP-1 gene expression both in vivo and in vitro and identifi ed the signaling transduction pathways. Our results showed that the insulin stimulated expression of both SHARP-1 and SHARP-2 genes. Further investigations showed that both a PI 3-K/atypical protein kinase C lambda (aPKCλ)/Jun N-terminal kinase (JNK)-and a PI 3-K/Rac/JNK-signaling pathway are thought to play pivotal roles in this induction process.
Materials and Methods
▼
Materials
Streptozotocin (STZ) was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The Humalin N, a human insulin, was purchased from Eli Lilly Japan K. K. (Kobe, Japan). Dulbecco's modifi ed Eagle's medium (DMEM), fetal bovine serum, insulin, LY294002, and dexamethasone (Dex) were purchased from Sigma-Aldrich (Saint Louis, USA). Streptomycin and penicillin G were purchased from Meijiseika (Tokyo, Japan). Wortmannin, rapamycin, staurosporine, PD98059, okadaic acid, Rac1 inhibitor, JNK inhibitor II, actinomycin D, and cycloheximide were purchased from Merck chemicals (Darmstadt, Germany). The Adeno-X rapid titer kit was purchased from Clontech (Palo Alto, USA). The TRIzol reagent was purchased from Invitrogen (Groningen, the Netherlands). High Capacity RNA-to-cDNA Kit was purchased from Applied Biosystems Japan (Tokyo, Japan). FastStart Universal SYBR Green Master (Rox) and GenoPure Plasmid Maxi kit were purchased from Roche Diagnostics (Indianapolis, USA). The pCMV-Tag2C plasmid was obtained from Stratagene (La Jolla, USA). The phRLuc-CMV plasmid and Dual Luciferase Reporter Assay System were obtained from Promega (Madison, USA).
Animals and treatment
Male Sprague-Dawley rats (6-weeks-old, 160-180 g body weight) were used. Rats were housed in a photoperiod of 12-h of light and 12-h of darkness (from 20:00 h through 8:00 h). To determine eff ect of the insulin, STZ (60 mg/kg) was intraperitoneally administered to rats, and the onset of diabetes mellitus was then confi rmed by determining the level of blood glucose. Four days after the administration of STZ, insulin (40 units/kg) was intraperitoneally injected and the rats were sacrifi ced at 14:00 h. Treatment of the animals followed Matsumoto University guidelines.
Cells and cell culture
Rat H4IIE hepatoma cells were a generous gift from Dr. Daryl K. Granner (Vanderbilt University, USA). Cells were maintained in DMEM supplemented with 10 % fetal bovine serum and antibiotics (100 μg/ml streptomycin and 100 units/ml penicillin G) at 37 °C under 5 % CO 2 , 95 % atmosphere. One million of cells were cultured for 24 h in 6-cm dishes. Subsequently, the medium was replaced with serum-free DMEM and then cultured for another 24 h. The medium was replaced once more 2 h before the cells were treated with insulin. To elucidate signaling pathway(s), the following inhibitors were used: 50 μM LY294002, 0.2 μM wortmannin, 0.1 μM rapamycin, 0.1 μM staurosporine, 25 μM PD98059, 10 nM okadaic acid, 50 μM Rac1 inhibitor, 10 μM JNK inhibitor II, 0.8 μM actinomycin D, or 10 μM cycloheximide. After incubation for 15 min with inhibitors, 100 nM insulin was added to the medium, then cultured for an additional 2 h. The Ad-GFP, which expresses the green fl uorescence protein (GFP), was a generous gift from Dr. Jun-ichi Miyazaki (Osaka University, Japan) [ 18 ] . The Ad-dn aPKCλ, which expresses a dominant negative form of aPKCλ and the Ad-dn Rac 17 N, which expresses a dominant negative form of Rac1 were described previously [ 19 ] . These adenoviruses were purifi ed by ultracentrifugation, followed by dialysis against phosphate buff ered saline [ 20 ] . The titration of the adenovirus was carried out using the Adeno-X rapid titer kit. H4IIE cells were infected with each adenovirus at multiplicity of infection (m. o. i.) of 50. The cells were then cultured for another 48 h.
Preparation of total RNA and real-time polymerase chain reactions (PCRs)
Total RNA was isolated from various H4IIE cells with TRIzol reagent (Invitrogen). One microgram of total RNA was reverse-transcribed with the High Capacity RNA-to-cDNA Kit. The cDNAs were then subjected to real time quantitative-PCR using primers, FastStart Universal SYBR Green Master (Rox), and ABI PRISM 7300 Real Time PCR System. Nucleotide sequences of primers were as follows: SHARP-1 forward 5′-AGGAATCCCTCATTTGCAAGAG-3′ and reverse 5′-CAAGCTCCTTTTGGGTTTACACA-3′; 36B4 forward 5′-GGCGAC-CTGGAAGTCCAACT-3′ and reverse 5′-GGATCTGCTGCATCTG CTTG-3′, respectively. The expression levels of SHARP-1 mRNA were normalized to the level of 36B4 mRNA.
Plasmid construction
Oligonucleotides, 5′-CCGGGAATTCGAATGGACGAAGGAATCCCT-CATT-3′ and 5′-CCGGCTCGAGTCAGCCTCTTGGGCGCAGCGAC-3′, which contains a coding region of the rat SHARP-1, were synthesized. As a template, cDNA from H4IIE cells was employed. A PCR product was digested with Eco RI/ Xho I, then inserted into the Eco RI/ Xho I sites of the pCMV-Tag2C to obtain pCMV-Tag2C-SHARP-1. Transfections and luciferase assays DNA transfections for H4IIE cells were carried out by the calcium phosphate method as described previously [ 21 ] . All plasmids used for transfection were prepared using the Genopure Plasmid Maxi Kit. H4IIE cells were co-transfected with 9 μg of the reporter plasmid, and 0.5 μg of the phRLuc-CMV in the absence or presence of 1 μg of an eff ector plasmid. Four hours after transfection, the cells were subjected to a 20 % dimethyl sulfoxide shock for 4 min and then maintained in serum-free DMEM supplemented with 1 μM Dex for an additional 16 h. In the case of analysis of insulin eff ect, the cells were treated with or without 100 nM insulin for another 6 h. Firefl y and sea pansy luciferase assays were measured using the Dual Luciferase Reporter Assay System according to the protocol supplied by the manufacture. Firefl y luciferase activities were normalized by sea pansy luciferase activities.
Statistical analysis
Data were represented as the mean and standard error and analyzed by one-way ANOVA followed by Fisher's protected LSD multiple comparison test. All experiments were repeated at least 4 times. H4IIE cells were treated for 2 h with various concentrations of insulin. The expression levels of SHARP-1 mRNA increased by insulin in a dose-dependent manner, and reached approximately 3-fold at 100 nM ( • ▶ Fig. 1b ) . The time course for the increase in the level of SHARP-1 mRNA was determined using 100 nM insulin. As shown in the • ▶ Fig. 1b , the level of SHARP-1 mRNA increased 2-fold by 1 h, and reached the plateau level at 2 h. These data indicate that insulin rapidly induces the expression of the rat SHARP-1 gene.
Results
▼
Insulin induces the rat SHARP-1 gene expression both in vivo and in vitro
Eff ects of various inhibitors on insulin-induced SHARP-1 mRNA expression
To identify the signaling pathway(s) that mediates the induction of SHARP-1 mRNA by insulin, H4IIE cells were treated with various inhibitors of insulin signaling molecules. As shown in • ▶ Fig.   1c , the PI 3-K inhibitors, LY294002 and wortmannin, completely abolished the insulin eff ect. An inhibitor of protein kinase C (PKC), staurosporine, also blocked the increase of SHARP-1 mRNA level by insulin. In addition, Rac1 inhibitor and a Jun N-terminal kinase inhibitor, JNK inhibitor II, decreased to 66.3 % and 22.5 %, respectively. In contrast, the insulin eff ect was unaffected by the addition of rapamycin, PD98059, or okadaic acid. These results suggest that multiple signaling molecules, such as PI 3-K, PKC, Rac1, and JNK mediate the accumulation of SHARP-1 mRNA by insulin.
Accumulation of SHARP-1 mRNA by insulin is required for both de novo RNA and protein synthesis
We then examined the issue of whether the induction of SHARP-1 mRNA by insulin is required for de novo RNA and/or protein synthesis. H4IIE cells were treated with an inhibitor of RNA polymerase II, actinomycin D, or a protein synthesis inhibitor, cycloheximide. The induction of SHARP-1 mRNA by insulin was completely inhibited by both reagents ( • ▶ Fig. 1c ). These results suggest that the induction of SHARP-1 mRNA by insulin was regulated at the transcription level and protein synthesis was required for the induction.
The role of aPKCλ in the induction of SHARP-1 gene expression by insulin
PKC has many isoforms and the aPKCλ is one of downstream PI 3-K pathway signaling molecules of insulin action [ 22 ] . We therefore investigated an issue of whether aPKCλ participates in the accumulation of SHARP-1 mRNA by insulin using the adenovirus system. The Ad-GFP and the Ad-dn aPKCλ were employed. Expressions of GFP and a dominant negative form of aPKCλ were confi rmed using an observation with a fl uorescence microscopy and Western blot analysis. When cells were infected with the Ad-GFP, the induction of SHARP-1 mRNA by insulin was not aff ected ( • ▶ Fig. 2 ). In contrast, when H4IIE cells were infected with the Ad-dn aPKCλ, an induction of SHARP-1 mRNA by insulin was decreased to 28.2 % ( • ▶ Fig. 2 ). These results indicate that aPKCλ contributes to the induction of the SHARP-1 gene expression by insulin.
The role of Rac1 in the insulin-induction of SHARP-1 gene expression
Rac, a member of the Rho family of small GTPases, is divided into 3 major classes: Rac1, Rac2, and Rac3 [ 23 ] . Rac1 act as a molecular switch in mediating multiple cellular mechanisms such as actin cytoskeletal organization and transcriptional regulation of genes [ 24 ] . The small GTPase Rac1 is another downstream eff ector of PI 3-K signaling pathway [ 25 -27 ] . We next examined the eff ect of a dominant negative form of Rac1 on insulin-induced SHARP-1 gene expression. When H4IIE cells were infected with the Ad-dn-Rac 17N, the accumulation of SHARP-1 mRNA by insulin was decreased to 15.9 % ( • ▶ Fig. 2 ). In contrast, when the cells were infected with the Ad-GFP, the induction of SHARP-1 mRNA by insulin was unaff ected ( • ▶ Fig. 2 ). These results indicate that Rac1 also play an important role in the expression of the rat SHARP-1 gene induction by insulin.
SHARP-1 represses transcription from the rat PEPCK gene promoter
We fi nally examined eff ects of SHARP-1 on the PEPCK gene promoter since insulin inhibits transcriptional activity of the PEPCK gene [ 28 ] . We fi rst confi rmed that the inhibition of the PEPCK gene promoter by insulin with luciferase reporter assays. H4IIE cells were transfected with the prPEPCK/Luc, which contains nucleotide sequences between − 467 and + 69 of the rat PEPCK gene. This region contains all elements required for hepatic expression and hormonal regulation. When the cells were treated with or without 100 nM insulin, promoter activity of the PEPCK gene decreased to 34.4 % by an insulin treatment ( • ▶ Fig. 3 ). We then analyzed the function of SHARP-1 on the PEPCK gene promoter. A cytomegalovirus enhancer/promoter-directed SHARP-1 expression plasmid, pCMV-Tag2C-SHARP-1, was co-transfected with 2 reporter plasmids into H4IIE cells. Nucleotide sequences between − 59 and + 50 of the mouse zinc-fi ngers and homeoboxes (ZHX) 1 gene was inserted into a luciferase reporter plasmid to give pmZHX1/Luc59 plasmid. When the pCMV-Tag2C plasmid, an empty vector for SHARP-1 expression plasmid, was transfected with the reporter plasmid, the relative luciferase activity was set to 100. As shown in • ▶ Fig. 3 , when the prPEPCK/ Luc was co-transfected with pCMV-Tag2C-SHARP-1, the luciferase activity was decreased to 15.5 %. In contrast, when the pmZHX1/Luc59 was co-transfected with the pCMV-Tag2C-SHARP-1, the luciferase activities remained unchanged. Theses results indicate that SHARP-1 specifi cally aff ects the transcription of the PEPCK gene promoter.
Discussion and Conclusions
▼
In the present study, regulatory mechanisms of the rat SHARP-1 gene expression by insulin were analyzed. We examined regulation of SHARP-1 mRNA level by insulin both in vivo and in vitro.
Insulin rapidly increased the level of SHARP-1 mRNA ( • ▶ Fig. 1a,   b ). We previously reported that insulin induced the SHARP-2 gene expression [ 16 ] . Thus, insulin can increase the levels of both SHARP-1 and SHARP-2 mRNAs. We then identifi ed which signaling pathways are involved in the increase of the level of SHARP-1 mRNA stimulated by insulin. Pretreatment of H4IIE cells with two pharmacological inhibitors of PI 3-K activity completely blocked the induction ( • ▶ Fig. 1c ). In addition, one of the downstream signaling molecules was suggested to be PKC since the inhibitor of PKC, staurosporine, strongly inhibited the levels ( • ▶ Fig. 1c ). PKC has many isoforms; classical PKC, novel PKC, and atypical PKC. Of these, it has been reported that aPKCλ is a downstream molecule of PI 3-K in hepatocytes and skeletal muscle [ 22 , 29 ] . To examine an issue of whether aPKCλ is involved in the up-regulation of the SHARP-1 gene expression by insulin, an adenovirus expressing a dominant negative form of aPKCλ that lacks the N-terminal region of wild-type protein was employed. An infection with the virus leads to block the insulin eff ect, indicating that a PI 3-K/aPKCλ pathway played a pivotal role in the regulation of the SHARP-1 gene expression by insulin ( • ▶ Fig. 2 ). In contrast, an induction of the rat SHARP-2 gene by insulin was inhibited by treatments with PI 3-K inhibitors but not a PKC inhibitor [ 16 ] . Therefore, insulin induces the expressions of both genes by diff erent mechanisms. The small GTPase Rac1 and JNK are also downstream eff ectors of a PI 3-K in insulin signaling pathway [ 26 , 30 ] . Pretreatment with a pharmacological inhibitor of Rac1 was partially blocked the induction ( • ▶ Fig. 1c ). In addition, an infection with an adenovirus expressing a dominant negative form of Rac1 prevented the activation on the SHARP-1 gene expression by insulin, indicating that a PI 3-K/Rac1 pathway also contributed to the insulin action. Since inhibitors of JNK almost blocked the insulin eff ect, we presumed that both a PI 3-K/aPKCλ pathway and a PI 3-K/Rac1 pathway were integrated to JNK as a downstream eff ector ( • ▶ Fig. 4 ).
The induction of the level of SHARP-1 mRNA by insulin was completely blocked by pretreatments of actinomycin D and cycloheximide. These results suggested that the insulin eff ect was controlled at the transcription level of the rat SHARP-1 gene and synthesis of a transcription factor(s) was required for the insulin-induced transcription of the rat SHARP-1 gene. In the case of the rat SHARP-2 gene, insulin stimulated the transcription level and de novo protein synthesis is not required for the regulation [ 16 ] . It has been reported that the 1.5 kb promoter region upstream of the rat SHARP-1 gene contains some transcriptional regulatory elements indispensable for the basal expression and regulation by hypoxia [ 12 , 31 , 32 ] . In our preliminary experiments, we examined to identify an insulin-response element of SHARP-1 gene in a luciferase reporter assay. However, the region between − 1 501 and − 1 of the rat SHARP-1 promoter was not responsible for the insulin-induced transcription (data not shown). It is well known that the promoter activity of PEPCK gene is repressed by insulin [ 33 , 34 ] ( • ▶ Fig. 3 ). PEPCK is considered a key enzyme in gluconeogenesis and the mechanisms of hormonal regulation of transcription for the PEPCK gene have been extensively studied. Forkhead box O1 (FOXO1) and SREBP-1c are well known insulin-regulatable transcription factors [ 35 -37 ] . Although FOXO1 is considered to stimulate the PEPCK gene transcription thereby promoting gluconeogenesis in the liver, insulin induces the translocation of FOXO1 from nuclei to cytoplasm, the PEPCK gene transcription was decreased. We also reported that overexpression of SHARP-2 in the primary cultured rat hepatocytes and H4IIE cells decreased both the level of PEPCK mRNA and the promoter activity of the PEPCK gene [ 6 ] . Since both SHARP-1 and SHARP-2 form a heterodimer, a formation of the SHARP-1/SHARP-2 heterodimer should be enhanced in H4IIE cells treated with insulin [ 38 ] . Therefore, it raises a possibility that SHARP-1 also repressed the PEPCK gene expression. Indeed, SHARP-1 specifi cally repressed the transcription of the rat PEPCK gene promoter ( • ▶ Fig. 3 ). The degree was comparable to an insulin eff ect ( • ▶ Fig. 3 ). Both SHARP-1 and SHARP-2 were shown to be transcription factors repressing the rat PEPCK gene promoter in an insulin-dependent manner. SHARP-1 inhibited transcription from the PEPCK gene promoter stronger than that of SHARP-2 ( • ▶ Fig. 3 and [ 6 ] ). This suggests that SHARP-1 may be a more important factor in the rapid transcriptional repression of the PEPCK gene. We conclude that insulin induces the expression of the rat SHARP-1 gene at the transcription level via both a PI 3-K/aPKCλ/ JΝΚ pathway and a PI 3-K/Rac/JNK pathway and that SHARP-1 represses promote activity of the PEPCK gene. Further studies Transcriptional regulation by SHARP-1. H4IIE cells were cotransfected with a luciferase reporter plasmid, and the phRLuc-CMV plasmid in the absence or presence of the eff ector plasmid. The prPEPCK/ Luc and pmZHX1/Luc59 plasmids were used as luciferase reporters. The pCMV-Tag2C (-) and pCMV-Tag2C-SHARP-1 ( + ) were used as the eff ector plasmids. A value of 100 was assigned to the promoter activity of each reporter plasmid in the absence of 100 nM insulin or pCMV-Tag2C-SHARP-1. Each column and bar represents the mean and standard error of four transfection experiments. a, b: p < 0.05.
will be required for the identifi cation of the insulin-response element of the rat SHARP-1 gene to fully understand the transcriptional regulatory mechanism by insulin. 
